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Background/aim: The present study aimed to determine the association between attention-deficit hyperactivity disorder (ADHD)
symptoms severity, fibromyalgia (FM) severity, and QoL.
Materials and methods: While the FM group consisted of 113 (74%) patients, the control group consisted of 40 (26%) individuals. FM
symptom severity, ADHD symptom severity, and QoL were evaluated using the fibromyalgia impact questionnaire (FIQ), adult ADHD
self-report scale (ASRS), and World Health Organization quality of life scale-brief version (WHOQOL-BREF), respectively.
Results: It was found that the FM group had significantly higher scores on the ASRS than the control group (p < 0.05). There was
a significant difference in FIQ scores and three WHOQOL-BREF domain scores between the FM alone and comorbid FM/high
probability of ADHD groups (p < 0.05). We found a negative correlation between ASRS total scores and all other scale scores (except for
the social relationships domain score of the WHOQOL-BREF) and a positive correlation between ASRS total scores and FIQ scores in
FM patients. ADHD scores would mediate the relationship between depression severity and QoL.
Conclusions: Our findings indicated that the presence of ADHD symptoms was related to greater FM symptom severity and poorer
QoL. Also, ADHD scores would mediate the relationship between depression severity and QoL.
Key words: Adult attention deficit hyperactivity disorder, fibromyalgia, quality of life

1. Introduction
Attention-deficit/hyperactivity
disorder
(ADHD)
is a childhood-onset neurodevelopmental disorder
characterized by inattention, hyperactivity, and impulsivity.
ADHD affects approximately 5.29% to 7.10% of children
[1] and can persist into adulthood in up to 65% of cases
[2]. The hypodopaminergic state seems to play a central
role in ADHD. A great body of evidence demonstrates
that people with ADHD tend to be at greater risk for other
mental disorders [3] and metabolic conditions (such as
migraine and obesity) [4]. The other clinical condition in
individuals with ADHD is pain disorders. Individuals with
ADHD are more sensitive to pain than healthy controls.
Fibromyalgia (FM) is one of the most important pain
disorders [5].
FM is a widespread musculoskeletal pain disorder
accompanied by fatigue, stiffness, sleep disturbance, and
cognitive impairment [6]. In addition to these medical
conditions, FM patients often have other comorbidities
(including irritable bowel syndrome, interstitial cystitis,

and mood disorders) [7]. Thus, FM may impair quality of
life (QoL) and has a large economic burden worldwide [8].
It has been reported that FM affects 2.7% of the general
population [9] and is seen in individuals aged 20 to 55
years, with a female to male ratio of 6:1 [10]. The etiology
of FM has not been completely elucidated; however,
several studies have proposed the role of genetic factors.
Candidate genes relevant to the pathogenesis of FM
include serotonergic, dopaminergic, and noradrenergic
transporter polymorphisms of genes involved in pain
transmission (such as the dopamine D4 receptor gene,
catechol-O-methyltransferase, and serotonin transporter
[11,12]. FM is defined as “pain amplification syndrome,”
which contains increased spinal dorsal horn neuronal
activity and diminished descending inhibition [13].
Psychiatric disorders generally accompany FM.
Anxiety disorder and depression are among the most
common psychiatric disorders [14]. These disorders
have been related to a negative impact on fatigue, sleep,
pain, physical function, and QoL in FM [15]. Also, FM
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patients exhibit cognitive disturbances including poor
concentration, attention deficit, impaired short-term
memory, forgetfulness, word-finding problems, inability
to multitask, and fluency problems [16]. These cognitive
disturbances called fibrofog can more affect patients
than their widespread pain [17]. Although cognitive
disturbances are universally experienced by FM patients,
cognitive symptoms frequently remain underrecognized
and undertreated, partly because the neuropsychological
assessment of dyscognition is a complex process [18]. It has
been reported that the prevalence of cognitive impairment
is 2.5 times higher among FM patients compared with
patients with other rheumatologic disorders and that
76.4%–82.5% of FM patients can suffer from cognitive
difficulties [19]. Other studies showed that the rates of
“concentration difficulties” and “failed memory”, which
are the main symptoms of ADHD, were respectively 95%
and 93% in FM patients [2,20].
In light of this information, some data make it necessary
to evaluate the relationship between ADHD and FM.
First, similar neurotransmitter pathways (norepinephrine
and dopamine) has a crucial role in the etiology of both
disorders. Restless legs syndrome, which is considered
to be a dopamine dysregulation disorder [21], has been
reported in up to 33% of ADHD patients [22] and up to
31% of FM patients [23]. Second, cognitive disturbances
are a major clinical part of both disorders. Finally, casecontrol studies are reporting that ADHD medications are
effective in both ADHD symptoms and FM-related pain
[24]. Thus, we were aimed to determine the association
between ADHD symptoms severity, FM severity, and QoL.
Hypothesis:
(1) ADHD symptoms are more common in patients
with FM than in the control group.
(2) There was a negative correlation between the
ADHD symptoms severity and QoL, and a positive
correlation with the FM severity.
(3) ADHD scores would mediate the relationship
between depression severity and quality of life.
2. Materials and methods
2.1. Study design and participants
We used observational cross-sectional survey design. In
the study in which 153 participants were included; 113
were FM patients and 40 were the control group. The
age range of the participants was 18–65. Education and
Research Hospital Physical Medicine and Rehabilitation
Clinic was held in Konya/ Turkey between March 2019
and March 2020. Data of participants were randomly 113
female patients with FM were collected consecutively
from the physical medicine and rehabilitation unit. Both
data collection and assessment procedures were done
blindly. Participants who were newly diagnosed with
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FM were included in the study. The physician diagnosed
the FM according to the 2016 criteria established by
the American College of Rheumatology (ACR). Three
conditions must be met in order to be diagnosed
according to ACR: 1) having symptoms of similar severity
for at least 3 months; 2) widespread pain index (WPI)
≥7 and symptom severity scale (SSS) score ≥5 or WPI of
4–6 and SSS score ≥9; 3) Generalized pain in at least 4 of
the 5 regions. In addition, the presence of FM does not
exclude the presence of other diseases. Those with medical
conditions considered to contribute to FM symptomology
(such as thyroid disorders, rheumatoid arthritis, systemic
lupus erythematosus, inflammatory arthritis, sjögren’s
syndrome, myositis, and vasculitis) were excluded from the
study. Those who scored higher than the cut-off values for
mental health screening tools applied to the participants
by the physician and who had psychiatric complaints were
referred to the psychiatrist in terms of the presence of
ADHD and other psychiatric diagnoses. Those who had a
psychiatric diagnosis other than ADHD were not included
in the study. DSM-5 diagnostic criteria were used to
diagnose ADHD. Each participant’s psychiatric/physical
evaluation and psychometric tests were completed within
an average of 90 min. The control group was composed
of 40 age-matched patient relatives and hospital staff who
were subjected to the same exclusion criteria as for the FM
patients. There was no significant difference between the
two groups in terms of marital status, income level, and
educational level. Income level was classified into three
groups as low, medium and high, according to the latest
data from the relevant institutions in Turkey. A total of 217
patients with FM were evaluated for participation in the
study. However, 104 of them were excluded from the study,
15 because of refusing participation and 89 because of not
meeting the inclusion criteria.
The sociodemographic data collection form, adult
ADHD self-report scale (ASRS), fibromyalgia impact
questionnaire (FIQ), World Health Organization quality
of life scale-brief version (WHOQOL-BREF), and hospital
anxiety and depression scale (HADS) were used to evaluate
the study participants. Required permissions for this study
were obtained from the Local Ethics Committee of Selcuk
University.
2.2. Tools
2.2.1. Adult ADHD self-report scale (ASRS)
It was developed for screening ADHD in adults by the World
Health Organization [25]. It was designed to investigate the
prevalence of ADHD in the general population and was
recommended for use in primary screening clinical trials
on ADHD. It is a short self-administered questionnaire
that is based on existing symptoms, unlike tools that
retrospectively define childhood ADHD. It is rated using
a five-point Likert scale (never (0), rarely (1), sometimes
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(2), often (3), and very often (4) and has two subscales
with each subscale consisting of nine questions (‘attention
deficit’ and ‘hyperactivity/impulsivity’). These questions
are created to determine how often each symptom happens
within the last 6 months. It was reported that those with
scores of 24 or higher from any of the two subscales had “a
high probability of ADHD” (ADHD), those with scores of
17–23 had “likely ADHD”, and those with scores of 0–16
had no ADHD. The validity and reliability of the Turkish
version of the scale were made by Doğan et al. [26]. The
Cronbach’s alpha coefficient of the translated and original
versions were 0.88 and 0.70.
2.2.2. Fibromyalgia impact questionnaire (FIQ)
It is a widely used scale to assess clinical severity in FM
patients. It is a Likert-type scale that evaluates 10 different
areas in FM patients. These areas are; anxiety, depression,
well-being, stiffness, fatigue, work difficulty, morning
tiredness, physical functioning, missed days of work, and
pain. The total score of the scale is between 0 and 100 and a
higher score indicates a more negative impact. Scores of 70
and above indicate severe engagement. FIQ was developed
by Burchardt et al. [27] and a validity and reliability study
was conducted for Turkish FM patients in 2000 [28]. The
Cronbach’s alpha coefficient of the translated and original
versions were 0.72 and 0.95, respectively.
2.2.3. Hospital anxiety and depression scale (HADS)
Anxiety and depression symptom levels of FM patients
were evaluated with HADS. HADS-A subscale is used for
anxiety symptoms and the HADS-D subscale is used for
depression symptoms. The maximum score is 21 on both
subscales, which are rated as a four-point Likert (0–3) and
consist of 7 items. Higher scores show increased anxiety
and depression symptom severity. The cutoff point was 7
for the depression subscale and 10 for the anxiety subscale.
The Turkish validation and reliability of this scale,
developed by Zigmond and Snaith [29], was made in 2003
[30]. The Cronbach’s alpha coefficient of the depression
and anxiety subscales were 0.77 and 0.85, respectively.
2.2.4. World Health Organization quality of life scalebrief version (WHOQOL-BREF)
It was developed as a 27-item short version of
WHOQOL-100 to reduce the burden on participants in
clinical trials. Turkish validity and reliability study of the
scale was published by Eser et al. [31]. It evaluates the
participants’ QoL in 5 different domains. These domains
are; physical health, general health, psychological wellbeing, social relationships, and the environment. Each
item is rated on a 5-point Likert scale. The scale, which
is converted with a total score between 0 and 100 points,
has no cutoff value. The Cronbach’s alpha coefficient were
calculated as 0.73 for the environmental domain, as 0.66
for the psychological domain, as 0.73 for the national

environmental domain, as 0.83 for the physical domain,
and as 0.53 for the social domain, respectively.
2.3. Statistical analysis
IBM SPSS-23 program was used for data analysis (SPSS
Inc; Chicago, IL, USA). Groups were compared using the
independent samples t-test for parametric continuous
variables (such as age and psychometric test scores)
and the chi-square test for categorical variables (such
as marital status, education, and ADHD rates). The
relationships between clinical variables and test scores
were analyzed using the Pearson correlation coefficients.
The bootstrap method of Preacher and Hayes (2008) was
used to determine the significance of the mediation effect
in the study [32]. SPSS Macro Process program was used
to calculate the Bootstrap method. Five thousand preloads
were made in the calculation of the intermediary effect.
Hayes’ (2013) Model 4 was used to identify the mediating
role of ADHD scores in the effect of depression severity
on quality of life [33]. Confidence intervals without zero
indicate that the mediating effect is significant [32]. We
also used the Sobel test to test significance of the mediation
effect [34]. Probabilities less than 0.05 were used as the
level of statistical significance in the analyzes.
3. Results
While the FM group consisted of 113 (74%) patients,
the control group consisted of 40 (26%) individuals. The
mean age was 41.38 ± 9.86 years in the FM group and
40.52 ± 10.72 years in the control group. No significant
differences were found in age, education level, and marital
status between the two groups (Table 1).
ADHD was detected in 38.9% (n = 44) of the FM group
and in 5% (n = 2) of the control group (p < 0.001). It was
found that the FM group had significantly higher scores on
the ASRS, all WHOQOL-BREF domains, HADS-A, and
HADS-D than the control group (p < 0.05) (Table 2).
The FM group was further divided into two subgroups
as FM alone and comorbid FM/ADHD. There was a
significant difference in FIQ scores and three WHOQOLBREF domain scores (general health/ psychological health/
physical health) between the FM alone and comorbid FM/
ADHD groups (p < 0.05) (Table 3).
In the analysis using the Pearson correlation coefficient,
there was a high negative correlation between the ASRS
total score and all other subscales of the WHOQOL-BREF
(except for the social relationships domain score) and
a high positive correlation with the FIQ, HADS-A, and
HADS-D. The results of the Pearson correlation analysis
are shown in Table 4.
Hypothesis 3 predicted that ADHD scores would
mediate the relationship between depression severity and
QoL. To test this hypothesis, the SPSS process mediation test
was performed to evaluate the mediation effect of ASRS-
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Table 1. Descriptive statistics of FM and control groups.
Participants
Age
Educational level of the Patients, (n%)
Primary school
Secondary school
High school
University
Marital Status, (n%)
Married
Single
Level of income (per month), (n%)
Low (<1000 $)
Middle(1000$<, <2000$)
High (>2000$)
Work, (n%)
Work
Not work

FM
(n=113)

Control
(n=40)

41.38± 9.86

40.52 ± 10.72

11 (9.7%)
27 (23.9%)
48 (42.5%)
27 (23.9%)

3 (7.5%)
12 (30.0%)
16 (40.0%)
9 (22.5%)

98 (86.7%)
15 (13.3%)

34 (85.0%)
6 (15.0%)

Statistical Analyses
p = 0.63
p = 0.84

t=0.48
x2=0.805

p = 0.78 x2=0.740

p = 0.50 x2=1.385
37 (32.7%)
63 (55.8%)
13 (11.5%)

16 (40.0%)
18 (45.0%)
6 (15.0%)
p = 0.89 x2=0.016

55 (48.7%)
58 (51.3%)

19 (47.5%)
21 (52.5%)

Table 2. Analysis of variables between FM and control groups for WHOQOL-BREF, ASRS, and HADS scores.

Participants screened
WHOQOL-GH
WHOQOL-PH
WHOQOL-P
WHOQOL-E
WHOQOL- SR
HADS_A
HADS_D
ASRS TOTAL
ASRS ATTENTION
ASRS HYPERACTIVITY/IMPULSIVITY

FM

Controls

Statistical analyses

113
39.00 ± 19.85
44.82 ± 17.42
53.11 ± 17.26
60.54 ± 15.43
53.77 ± 15.71
10.55 ± 4.35
8.16 ± 3.45
25.60 ± 12.86
10.61 ± 4.99
14.90.13 ± 9.24

40
64.68 ± 13.54
75.44 ± 12.81
68.54 ± 12.40
70.93 ± 15.52
68.12 ± 16.44
5.70 ± 2.52
3.92 ± 2.84
14.12 ± 5.74
5.70 ± 3.36
8.42 ± 3.85

p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001

t = –7.574
t = –10.173
t = –5.193
t = –3.656
t = –4.504
t = 6.664
t = 6.980
t = 5.445
t = 5.775
t = 4.293

WHOQOL-GH: World Health Organization questionnaire on quality of life-general health, WHOQOL-P: World Health
Organization questionnaire on quality of life-psychological, WHOQOL-PH: World Health Organization questionnaire
on quality of life- physical health, WHOQOL-E: World Health Organization questionnaire on quality of life environment,
WHOQOL-SR: World Health Organization questionnaire on quality of life- social relationships, HADS-A: hospital anxiety
and depression scale-anxiety, HADS-D: hospital anxiety and depression scale-depression, ASRS: adult ADHD self-report scale

TOTAL between HADS-D and the WHOQOL-PH. Figure
A shows that the total effect of HADS-D on WHOQOL
-PH was significant (β = 0.18, t = 2.63, p = 0.010). The 95%
bias-corrected confidence intervals did not contain zero
(32), which revealed that ASRS-TOTAL was a mediator
in the relationship between HADS-D and the WHOQOLPH, [β = –0.82, % 95 CI (–1.7513, –0.0430)]. This indicates
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partial mediation. Partial mediation indicates that some
of the relationships between HADS-D on WHOQOLPH occurs directly, while others are indirectly based on
ASRS-TOTAL (32). The results of the mediation analyses
are presented in Figure B. Results of the Sobel test indicate
ADHD scores significantly mediated the relationship
between depression severity and QoL (Z = –2.33, p < 0.05).
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Table 3. Analysis of variables between alone FM and FM/ADHD groups for FIQ, WHOQOL-BREF, ASRS, and
HADS scores.
Alone FM

FM/ADHD

Statistical analyses

Participants screened, No. %)

69 (61.1%)

44 (38.9%)

FIQ

58.28 ± 16.50

74.50 ± 16.28

WHOQOL -GH

33.12 ± 12.46

WHOQOL PH

40.17 ± 16.97

WHOQOL-P

p < 0.001

t = –5.124

42.75 ± 21.00

p = 0.01

t = 2.577

47.78 ± 17.18

p = 0.02

t = 2.307

46.96 ± 15.88

57.02 ± 17.07

p = 0.02

t = 3.137

WHOQOL-E

58.59 ± 15.73

61.78 ± 15.22

p = 0.28

t = –0.397

WHOQOL SR

53.18 ± 15.33

54.54 ± 21.07

p = 0.69

t = 1.070

HADS-A

9.82 ± 4.59

11.70 ± 3.70

p = 0.02

t = 2.278

HADS-D

7.73 ± 3.42

8.84 ± 3.42

p = 0.10

t = –1.668

WHOQOL-GH: World Health Organization questionnaire on quality of life- general health, WHOQOL-P:
World Health Organization questionnaire on quality of life-psychological, WHOQOL-PH: World Health
Organization questionnaire on quality of life- physical health, WHOQOL-E: World Health Organization
questionnaire on quality of life environment, WHOQOL-SR: World Health Organization questionnaire on
quality of life- social relationships, HADS-A: hospital anxiety and depression scale-anxiety, HADS-D: hospital
anxiety and depression scale-depression, ASRS: adult ADHD self-report scale, FIQ: fibromyalgia impact
questionnaire.
Table 4. Pearson’s correlation coefficients for each pair of variables.
1

2

3

4

5

6

7

8

9

10

11

1. Age
2. WHOQOL-GH

–0.146

3. WHOQOL-P

–0.166 0.618**

4. WHOQOL-PH

–0.062 0.484**

0.593**

5. WHOQOL-E

–0.013 0.280

0.561**

0.478**

6. WHOQOL-SR

–0.167 0.112

–0.453**

0.193*

7. HADS-A

–0.135 –0.353

–0.471** –0.366

–0.273** –0.057

8. HADS-D

0.239*

–0.513**

–0.553**

–0.365**

-0.263**

–0.297** 0.367**

9. ASRS-T

–0.037 –0.259**

–0.370**

–0.433**

-0.212*

–0.066

0.275**

0.246**

10. ASRS-A

–0.058 –0.320

–0.390

–0.410

–0.145

–0.134

0.316

0.319**

11. ASRS-H/I

–0.015 –0.206*

–0.327**

–0.383**

–0.216*

–0.036

–0.216* 0.184

12.FIQ

0.162

**

**

**

0.370**
**

**

**

–0.582** –0.524** –0.616** -0.293** –0.110

**

0.410**

0.816**
–0.288**

0.947**

0.431** 0.557**

0.508**

0.508**

*Correlation is significant at the 0.05 level (two-tailed). **Correlation is significant at the 0.01 level (two-tailed).
WHOQOL-GH: World Health Organization questionnaire on quality of life-general health, WHOQOL-P: World Health Organization
Questionnaire on quality of life-psychological, WHOQOL-PH: World Health Organization questionnaire on quality of life- physical
health, WHOQOL-E: World Health Organization questionnaire on quality of life environment, WHOQOL-SR: World Health
Organization questionnaire on quality of life- social relationships, HADS-A: hospital anxiety and depression scale-anxiety, HADS-D:
hospital anxiety and depression scale-depression, ASRS T-A-H/I: adult ADHD Self-report scale total-attention-hyperactivity/
impulsivity, FIQ: fibromyalgia impact questionnaire.

4. Discussion
FM continues a complex pain disorder due to multiple
comorbidities. In our study, the effect mechanism of

ADHD symptoms presence on QoL in patients with
FM was evaluated. The possible mediating effect of
ADHD scores in the relationship between depression
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A
β=-1.84
t=-4.12
p=.0001

HADS-D levels

WHOQOL -PH levels

B
β=0.95
t=2.79
p=.006

HADS-D levels

ASRS-TOTAL

β=-1.37
t=-3.19
p=.001

β=-0.49
t=4.28
p<.001

WHOQOL -PH
levels

Figure. Mediator effects of ASRS. WHOQOL-PH: World Health Organization questionnaire on quality of life-physical health, HADS-D:
hospital anxiety and depression scale-depression, ASRS: adult ADHD self-report scale

symptoms severity and QoL has never been investigated
before.
The possible overlap of FM with ADHD is
underestimated, and thus the presence of ADHD in FM
patients may be underreported. Indeed, studies have
shown that the frequency of FM appears to be higher
among adults with ADHD compared to controls or
even patients with cognitive complaints without ADHD.
Conversely, adult ADHD is more commonly seen in FM
[35]. Persistent pain poses a definite effect on attention.
Moore et al. (2012) demonstrated that it influenced
complex attention performances (such as attention span,
attention shifting, and divided attention) rather than
simpler attention tasks [36]. Van Rensburg et al. found that
44.7% of patients with FM were diagnosed with comorbid
adult ADHD according to the ASRS v1.1 [37]. Another
study showed that 25% of FM patients had co-occurring
ADHD [38]. Our study found that the rate of ADHD in
patients with FM was 38.9%.
This higher level of coexistence requires a common
pathogenic perspective for both conditions. The common
comorbidity of FM and adult ADHD can produce various
therapeutic effects, as defects in dopaminergic circuits
have been implicated in both cases. For instance, FM is
associated with reduced repetition of the dopamine D4
receptor gene (DRD4), which is normally characterized
by seven polymorphic repeats [39]. These seven repetitive
variations are related to thinner right orbitofrontal,
inferior prefrontal, and posterior parietal cortex in ADHD
[40]. FM is characterized by decreased activity of the
descending pain inhibitory pathways and low levels of
dopamine, serotonin, norepinephrine, and endogenous
opioids [41]. ADHD is characterized by abnormal
neurodevelopmental processes that affect attention,
emotion, and somatosensory functions, especially in
frontostriatal, frontoparietotemporal, frontocerebellar,
and frontolimbic regions. Both dopaminergic and
noradrenergic systems are responsible for the greatest
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impairment in ADHD [42]. The other problematic area for
both cases is emotional regulation. Deficits in recognition,
regulation, and expression of emotions are one of the main
problems in both ADHD and FM [43]. For the reasons
mentioned above, the common etiologic factors that may
be effective in the etiology and symptom severity of FM
should be evaluated in each patient.
Another perspective in the relationship between
ADHD and FM is that pain affects cognitive structures
by disrupting working memory [44] and can be the best
indicator for objective results of cognitive function test
[45]. Pain is considered a high-priority signal. It is thought
that pain slows, stops, or impairs behavior when high
cognitive demand is present [46]. Cognitive impairment
in FM cannot be fully explained by pain. Other underlying
factors contain anxiety, depression, sleep, and fatigue
[47]. Therefore, early intervention for problems other
than cognitive deficits is very important for preventing
cognitive disturbances in FM.
The fact that ADHD symptoms increase the severity
of FM symptoms and worsen QoL in patients with FM
is one of the important data from our study. In a recent
study examining this relationship, ADHD symptoms were
indicated to be associated with poor functionality in patients
with FM. This relationship was even more pronounced in
the presence of depression and anxiety symptoms [48]. In
another study, the presence of comorbid ADHD was found
to be associated with increased severity of FM symptoms
and increased impairment in functionality [49]. Although
some observations have previously been conducted for
the link between adult ADHD and FM based on shared
cognitive deficits, a small number of studies have been
performed on the level of QoL and ADHD severity in FM
patients. In addition to the fact that ADHD symptoms are
more frequent in FM patients, our study demonstrated that
the increased severity of ADHD symptoms would pose a
negative impact on multiple domains of the QoL. Our study
also showed that the general health, psychological health,

TÜRKOĞLU and SELVİ / Turk J Med Sci
physical health, environment domains of the WHOQOLBREF strongly correlated with ADHD symptom severity.
Until recently, cognitive dysfunction experienced by
FM patients has been largely ignored due to the lack of
diagnostic criteria. Cognitive dysfunction, such as memory
and attention, can sometimes dramatically change the lives
of FM patients. Patients with FM often report declines in
cognitive function, memory, and mental alertness as well
as forgetfulness that have been called “fibro fog”, which can
be more disruptive than pain. Therefore, it should be one
of the most important parts of clinical assessment in FM
patients [19].
In the present study, it is revealed that ADHD scores of
the patients with FM have a partial mediating effect in the
relationship depression severity and physical quality of life.
It has been shown in many studies that FM patients show an
increased rate of anxiety and depressive symptoms besides
their cognitive symptoms [50]. In fact, depressive disorder
is the most common comorbidity with a prevalence of
20%–80% [51]. It has been shown that somatic symptom/
pain is more common when it accompanies depression in
FM patients, related to the “pain relief hypothesis” [15,52].
The presence of these comorbidities is important in that
they seriously affect the QoL [53], apart from making
treatment difficult. Emotion regulation problems, which
are key components in ADHD, may cause sensitivity to
depressive symptoms [54]. In addition, due to the cognitive
and emotional symptoms of ADHD in FM patients,
dysfunctional coping mechanisms may contribute to the
development of depressive symptoms. While evaluating
the psychical QoL, which is an important target in the FM
management process, consideration of ADHD can make
a significant contribution to treatment and prognosis.
Our findings revealed that depression has an effect on

QoL through ADHD symptoms. It can be interpreted
that intervention in emotion regulation deficits/emotional
responsiveness and other features mediating ADHDrelated depression may have an effect on QoL in patients
with FM.
The present study has several limitations. First, it was
not possible to exclude the influence of confounding factors
such as physical exercise, sleep habits, and eating behavior.
Second, our study included a relatively small number of
subjects. Another limitation of our study is that all patients
were not evaluated with a structured psychiatric interview.
Furthermore, the absence of male FM patients in our study
may limit the generalizability of the results. Finally, the
relationship between FM and hyperactivity/impulsivity
were not adequately addressed, but the attention and
related factors were mainly evaluated.
In conclusion, our findings indicated that in FM
patients with ADHD, FM symptom severity is higher
and the QoL is worse. Also, the partial mediating effect
of ADHD symptom severity in the relationship between
depression severity and physical QoL is an important
finding. Thus, in FM patients may not respond adequately
to standard treatment if their ADHD symptoms are not
taken into consideration.
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